Events & News

GENSPEED will present at Medica/Compamed 2023 in Düsseldorf from November 13th to 16th 2023! Meet with us to learn about our latest tests and to discuss how we can help you develop fast and reliable multiplex tests that meet your customers’ needs. See you in Düsseldorf!

NEWS from the Vitamin D xPOC test

The suPARnostic POC+

Great news suPARnostic POC+ Test based on GENSPEED technology now available!

GENSPEED Biotech GmbH, CEO, Max Sonnleitner says: “We are excited to see the commercial launch of suPARnostic® POC+ and the positive clinical data from the Greek study, which demonstrates the ability to run suPAR analysis on GENSPEED devices near patients with reliable results that can be obtained in just 20 minutes out of a drop of blood. This is an important milestone in our collaboration with ViroGates, and we look forward to continuing our work together to incorporate additional relevant biomarkers in multiplex tests in the future”

Original post:

suPARnostic POC+

COMPAMED 14.-17. November 2022



We are at the COMPAMED in Düsseldorf -melting pot for high-tech solutions in the medical technology sector!

Even twice 😉

You can meet us in Hall 8A

    • at the Microfluidics Innovation Hub (booth K32) and
    • at MedPhab (booth # F35.1)




Compamed 2022 Microfluidics

NEW! FSME/TBE IgG xPOC antibody test

Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021 - a feasible surveillance startegy for post-pandemic monitoring?

Abstract: …The aim of this study was to estimate the prevalence of SARS-CoV-2-specific immunoglobulin G antibodies in the federal state of Upper Austria (Austria) during the period of December 2020 until April 2021. To achieve this goal, we have analyzed anonymized data on the immune status of self-referral volunteers that have been determined at local pharmacies through a low-entry-barrier point-of-care analysis approach. The seroprevalence values for immunoglobulin type G antibodies against SARS-CoV-2 antigens obtained by rapid diagnostic testing on peripheral blood from volunteers reflect the current population-based estimates reported in the literature as well as the positivity rates detected by PCR-screening analyses. In conclusion, broad-based monitoring of IgG antibodies by means of a point-of-care testing network represents a valuable tool to assess the current immune situation within regionally defined populations.